Skip to main content
TMDXTransMedics Group, Inc.Sell5.9·$72.00
TMDX · Decision

Should you buy TransMedics Group (TMDX)?

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
5.9/10
Price
$72.00
Entry / Take Profit (TP) / Stop Loss (SL)
/ $99.18 / $67.20

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

  • Wide Moat High RoeStable
  • Revenue Growth MomentumTrippedStable
  • Extreme Bearish PositioningDeteriorating
  • +1 more pillar — see the Why tab for full reasoning

→ Full pillar scorecard with all 4 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Wide Moat High Roe

    Trip ifReturn on equity falls below 20%, declining more than 55% from the current 45%, signaling meaningful deterioration in capital efficiency.

  • P2Revenue Growth MomentumTripped

    Trip ifYear-over-year revenue growth falls below 10% in at least 2 of the next 4 quarters, signaling significant deceleration from the 21% pace.

  • P3Extreme Bearish Positioning

    Trip ifShort interest rises above 40%, exceeding the already elevated 33% by more than 7 percentage points, confirming a deepening of bearish positioning.

  • P4Analyst Upside Recovery Path

    Trip ifAnalyst consensus price target falls below $65, more than 13% below the current price of $75.48, removing the upside asymmetry entirely.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for TransMedics Group, Inc. (TMDX) is SELL_IF_HOLDING with medium conviction, score 5.9/10 at $72.00. The F-path SELL output reflects an overall score of 4.9 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 3.63 is supplementary context, not the trigger.

2. What would change the verdict

SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.

3. What the engine sees

On the bull side: Strong earnings beat streak (3/4); Positive insider activity; Wide economic moat. On the bear side: Concentration risk — Supplier: third-party sterilization vendors; Leverage penalty (D/E 1.7): -1.0; Weak growth.

4. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $72.00, with structural invalidation at $67.20. The asymmetric R:R against a reversal hypothesis is 3.63 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates TMDX — 10-dimension breakdown →

Bull case

  • Strong earnings beat streak (3/4)
  • Positive insider activity
  • Wide economic moat

Bear case

  • Concentration risk — Supplier: third-party sterilization vendors
  • Leverage penalty (D/E 1.7): -1.0
  • Weak growth
Home Stocks TMDX Buy or sell?